[HTML][HTML] Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study
O Pleguezuelos, E James, A Fernandez, V Lopes… - NPJ vaccines, 2020 - nature.com
FLU-v, developed by PepTcell (SEEK), is a peptide vaccine aiming to provide a broadly
protective cellular immune response against influenza A and B. A randomized, double-blind …
protective cellular immune response against influenza A and B. A randomized, double-blind …
Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers
Healthcare institutions with mandatory influenza vaccination policies have over 90%
vaccination rates among healthcare workers (HCWs) resulting in a population that has …
vaccination rates among healthcare workers (HCWs) resulting in a population that has …
Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers
Objective To compare the antibody response to influenza between health care workers
(HCWs) who have received multiple vaccinations (high vaccination group) and those who …
(HCWs) who have received multiple vaccinations (high vaccination group) and those who …
Individual and population trajectories of influenza antibody titers over multiple seasons in a tropical country
The question of whether to permit private medical services (dubbed SHARAP) in
government hospitals is one of the most controversial issues in Israeli health care today, with …
government hospitals is one of the most controversial issues in Israeli health care today, with …
A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery …
GJ Gorse, S Grimes, H Buck, H Mulla, P White, H Hill… - Vaccine, 2022 - Elsevier
Background New influenza vaccines are needed to increase vaccine efficacy. Adjuvants
may allow hemagglutinin (HA) dose-sparing with enhanced immunogenicity. MAS-1 is an …
may allow hemagglutinin (HA) dose-sparing with enhanced immunogenicity. MAS-1 is an …
[HTML][HTML] Analysis of viral and host factors on immunogenicity of 2018, 2019, and 2020 southern hemisphere seasonal trivalent inactivated influenza vaccine in adults …
A Capão, ML Aguiar-Oliveira, BC Caetano, TK Neves… - Viruses, 2022 - mdpi.com
Annual vaccination against influenza is the best tool to prevent deaths and hospitalizations.
Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high …
Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high …
[PDF][PDF] Analysis of viral and host factors on immunogenicity of 2018, 2019, and 2020 southern hemisphere seasonal trivalent inactivated influenza vaccine in adults in …
A Capão, ML Aguiar-Oliveira, BC Caetano… - DOI: https://doi. org …, 2022 - academia.edu
Annual vaccination against influenza is the best tool to prevent deaths and hospitalizations.
Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high …
Regular updates of trivalent inactivated influenza vaccines (TIV) are necessary due to high …
MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross …
GJ Gorse, S Grimes, H Buck, H Mulla, P White, H Hill… - Vaccine, 2022 - Elsevier
Background Increased influenza vaccine efficacy is needed in the elderly at high-risk for
morbidity and mortality due to influenza infection. Adjuvants may allow hemagglutinin (HA) …
morbidity and mortality due to influenza infection. Adjuvants may allow hemagglutinin (HA) …
Influence of Preseason Antibodies Against Influenza Virus on Risk of Influenza Infection Among Healthcare Personnel
GJ Gorse, SM Rattigan, A Kirpich… - The Journal of …, 2022 - academic.oup.com
Background The association of hemagglutination inhibition (HAI) antibodies with protection
from influenza among healthcare personnel (HCP) with occupational exposure to influenza …
from influenza among healthcare personnel (HCP) with occupational exposure to influenza …
[HTML][HTML] Baseline levels of influenza-specific b cells and T cell responses modulate human immune responses to swine variant influenza A/H3N2 vaccine
L Lai, N Rouphael, Y Xu, AC Sherman, S Edupuganti… - Vaccines, 2020 - mdpi.com
The cellular immune responses elicited by an investigational vaccine against an emergent
variant of influenza (H3N2v) are not fully understood. Twenty-five subjects, enrolled in an …
variant of influenza (H3N2v) are not fully understood. Twenty-five subjects, enrolled in an …